# NCT05631262 (NCT05631262)

> SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05631262
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Conditions: Selected Subjects With Advanced Solid Tumors
- Interventions: SKB264; Docetaxel
- Enrollment: 321
- Primary outcome: Objective Response Rate (ORR)
- Primary outcome: Incidence and severity of adverse events (AEs)

## Commentary we found

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05631262